Table 1.
Baseline characteristics of subjects before and after matching
| Variables | Before Matching | After Matching | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| With Death (n = 115) | Without Death (n = 3,131) | P-value | With Death (n = 94) | Without Death (n = 94) | P-value | |
| Male, n (%) | 64 (55.65%) | 2116 (67.60%) | 0.009 | 53 (56.38%) | 48 (51.06) | 0.465 |
| Age (years) | 77.46 ± 11.48 | 66.14 ± 12.39 | < 0.001 | 76.61 ± 11.98 | 76.88 ± 9.04 | 0.029 |
| BMI (kg/m2) | 23.95 ± 3.10 | 25.51 ± 3.55 | < 0.001 | 23.93 ± 3.25 | 24.73 ± 3.91 | 0.018 |
| SBP (mmHg) | 131.75 ± 31.75 | 139.61 ± 24.91 | 0.006 | 134.17 ± 30.24 | 141.96 ± 26.85 | 0.213 |
| Previous stroke, n (%) | 13 (11.30) | 131 (4.18%) | < 0.001 | 11 (11.70%) | 15 (15.95) | 0.398 |
| Blood Pressure class, n (%) | 0.544 | 0.628 | ||||
| Normal | 37 (32.20%) | 923 (29.50%) | 31 (32.97%) | 34 (36.17%) | ||
| I | 17 (14.80%) | 578 (18.50%) | 21 (22.34%) | 15 (15.95%) | ||
| II | 10 (8.70%) | 355 (11.30%) | 9 (9.57%) | 7 (7.44%) | ||
| III | 51 (44.30%) | 1275 (40.70%) | 33 (35.10%) | 38 (40.42%) | ||
| HF, n (%) | 107 (93.00%) | 1725 (55.10%) | < 0.001 | 86 (91.48%) | 86 (91.48%) | / |
| Diabetes, n (%) | 59 (51.30%) | 1309 (41.80%) | 0.044 | 49 (52.12%) | 38 (40.42%) | 0.108 |
| HbA1c (%) | 6.79 ± 1.55 | 6.88 ± 1.64 | 0.58 | 6.83 ± 1.59 | 6.71 ± 1.60 | 0.724 |
| Acute coronary syndrome, n (%) | 0.051 | 0.463 | ||||
| NSTEMI | 74 (64.30%) | 2274 (72.60%) | 66 | 61 | ||
| STEMI | 41 (35.70%) | 857 (27.40) | 28 | 33 | ||
| Blood routine examination | ||||||
| Na (mmol/L) | 138.26 ± 5.78 | 139.86 ± 3.14 | < 0.005 | 138.46 ± 6.07 | 138.62 ± 3.55 | < 0.001 |
| K (mmol/L) | 4.15 ± 0.67 | 3.92 ± 0.46 | < 0.001 | 4.13 ± 0.69 | 3.99 ± 0.54 | 0.019 |
| PLT (109/L) | 215.15 ± 85.03 | 214.13 ± 60.52 | 0.89 | 212.48 ± 68.35 | 203.52 ± 60.22 | 0.169 |
| Neutrophils (109/L) | 9.10 ± 4.01 | 5.63 ± 2.54 | < 0.001 | 8.76 ± 3.81 | 5.98 ± 2.75 | 0.001 |
| Lymphocytes (109/L) | 1.23 ± 0.58 | 1.64 ± 0.61 | < 0.001 | 1.21 ± 0.62 | 1.45 ± 0.54 | 0.167 |
| eGFR (mL/min/1.73 m2) | < 0.001 | 0.487 | ||||
| > 60/n (%) | 40 (34.80%) | 2291 (73.20%) | 35 (37.23%) | 43 (45.74%) | ||
| 30-60/n (%) | 39 (33.90%) | 316 (10.10%) | 29 (30.85%) | 26 (27.65%) | ||
| < 30/n (%) | 36 (31.30%) | 524 (16.70%) | 30 (31.91%) | 25 (26.59%) | ||
| Blood biochemistry | ||||||
| TG (mmol/L) | 1.17 [0.92-1.69] | 1.43 [1.04-2.05] | < 0.001 | 1.17 [0.90-1.76] | 1.16 [0.95-1.77] | 0.847 |
| LDLC (mmol/L) | 2.27 [1.79-3.09] | 2.45 [1.87-3.04] | 0.323 | 2.23 [1.74-3.02] | 2.38 [1.84-3.14] | 0.402 |
| Apolipoprotein ratio | 1.37 [1.04-1.67] | 1.37 [1.13-1.71] | 0.177 | 1.36 [1.02-1.68] | 1.39 [1.16-1.77] | 0.178 |
| ALT (U/L) | 32.00 [16.10-81.28] | 24.13 [6.23-38.10] | < 0.001 | 29.72 [14.86-73.94] | 26.92 [17.04-47.25] | 0.441 |
| AST (U/L) | 81.91 [27.32-234.86] | 28.10 [19.45-62.56] | < 0.001 | 68.17 [23.99-198.17] | 43.12 [21.21-142.08] | 0.155 |
| CTNI (ug/L) | 5.52 [0.77-16.72] | 1.76 [0.82-3.23] | < 0.001 | 2.99 [0.62-8.53] | 3.23 [0.85-7.60] | 0.940 |
| In-Hospital treatment | ||||||
| Aspirin, n (%) | 98 (85.20%) | 2971 (94.90%) | < 0.001 | 79 (84.04%) | 82 (87.23%) | 0.533 |
| Statins, n (%) | 105 (91.30%) | 3084 (98.50%) | < 0.001 | 86 (89.36%) | 92 (97.87%) | 0.051 |
| ACEI, n (%) | 28 (24.30%) | 1556 (49.70%) | < 0.001 | 23 (24.46%) | 44 (46.80%) | 0.001 |
| Lymphocyte-based inflammatory indices | ||||||
| NLR | 7.36 [4.71-12.18] | 3.19 [2.29-4.78] | < 0.001 | 7.47 [4.79-11.76] | 3.62 [2.64-5.60] | < 0.001 |
| PLR | 170.83 [122.32-258.82] | 132.06 [103.39-170.72] | < 0.001 | 190.35 [121.98-268.53] | 142.47 [110.48-167.35] | < 0.001 |
Note: If the continuous data fitted a normal distribution, it was described by X ± SD; otherwise, it was described by the median and quartiles (25%, 75%). BMI, Body mass index; HF, heart failure; HbA1c, glycated hemoglobin; TG, triglyceride; LDLC, low-density lipoprotein cholesterol; Apolipoprotein ratio, apolipoprotein A-to-B ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTNI, cardiac troponin I; ACEI, angiotensin-converting enzyme inhibitors; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.